Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment.
Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals.
The collaboration integrates diagnosis, prescription, and home delivery into one platform.
Eli Lilly's executive vice president, Patrik Jonsson, emphasized the importance of affordability and accessibility in obesity care, noting that Zepbound's lower-cost vials represent a significant step toward breaking down barriers. "Our goal is to provide safe and effective treatment options that patients can trust," Jonsson stated.
"Lilly's release of Zepbound single-dose vials at a lower, self-pay-only price was groundbreaking and reflects the patient-centric model upon which Ro was founded. This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home," said Zach Reitano, co-founder & CEO of Ro.
CNBC notes that the collaboration enables eligible patients to access Zepbound through a "complete end-to-end" experience. Patients can receive a diagnosis, obtain a prescription, and have the medication delivered directly to their homes via Gifthealth, a digital pharmacy partnered with LillyDirect.
Zepbound vials are cash-pay products priced at $399 for a 2.5 mg dose and $549 for a 5 mg dose.
Ro also provides extensive ongoing support for weight management, including personalized care plans, 24/7 access to licensed physicians, coaching, and tools for monitoring progress.
Using data, the platform helps patients choose the most cost-effective medication, whether through insurance or cash payment.
Ro additionally assists with prescriptions for Novo Nordisk A/S' (NYSE:NVO) rival drug, Wegovy (semaglutide), and compounded alternatives.
Last week, Eli Lilly revealed topline data from the SURMOUNT-5 phase 3b trial of Zepbound (tirzepatide) compared with Novo Nordisk's Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities.
Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.
Price Action: At last check Thursday, LLY stock was up 0.31% at $798.50.
远程医疗公司Ro已与礼来公司（纽约证券交易所代码：LLY）合作，以增加患者获得Zepbound（替西帕肽）单剂量小瓶进行肥胖治疗的机会。
通过LillyDirect，Ro将以自付价格为患者简化获得这种经美国食品药品管理局批准的药物的机会，从而使符合临床条件的个人更负担得起这种药物。
此次合作将诊断、处方和送货上门服务整合到一个平台中。
礼来公司执行副总裁帕特里克·琼森强调了肥胖症护理中可负担性和可及性的重要性，并指出，Zepbound的低成本药瓶是朝着打破壁垒迈出的重要一步。琼森说：“我们的目标是提供患者可以信赖的安全有效的治疗方案。”
“礼来公司以较低的自费价格发布的Zepbound单剂量小瓶具有开创性，反映了Ro创立时以患者为中心的模式。这种整合进一步简化了获得唯一获批准的双GIP和 GLP-1 受体激动剂的获取，患者无需离开 Ro 应用程序，更不用说离开家了。” Ro 联合创始人兼首席执行官扎克·雷塔诺说。
CNBC指出，此次合作使符合条件的患者能够通过 “完整的端到端” 体验访问Zepbound。患者可以通过与LillyDirect合作的数字药房Gifthealth获得诊断，获得处方，并将药物直接送到家中。
Zepbound小瓶是现金支付的产品，2.5毫克剂量的价格为399美元，5毫克剂量的定价为549美元。
Ro 还为体重管理提供广泛的持续支持，包括个性化护理计划、全天候联系持牌医生、指导和监测进展的工具。
该平台使用数据帮助患者选择最具成本效益的药物，无论是通过保险还是现金支付。
罗还协助开具诺和诺德A/S（纽约证券交易所代码：NVO）竞争对手药物Wegovy（索玛鲁肽）和复合替代品的处方。
上周，礼来公司公布了Zepbound（替西帕肽）的Surmount-5期30试验的主要数据，比较了诺和诺德的Wegovy（索玛鲁肽）治疗肥胖成年人或体重过重并有以下至少一种合并症的成年人。
与Wegovy相比，Zepbound的相对减重量增加了47％。平均而言，Zepbound的减肥效果优异，为20.2％，而Wegovy的减肥率为13.7％。
价格走势：在周四的最后一次检查中，LLY股价上涨0.31％，至798.50美元。
